Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
John P. Leonard(Institute of Genetics), John L. Ryan(Pfizer (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Matthew L. Sherman, Janice P. Dutcher(Lung Cancer Research Foundation), Gerald L. Fisher, Lynn J. Buchanan, G R Larsen(Aquinnah (United States)), Michael B. Atkins(Georgetown University)
PubMed
October 1, 1997
Cited by 814
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k